中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 183-186.doi: 10.35541/cjd.20200013
• 综述 • 上一篇
罗帅寒天 龙海 张桂英 陆前进
收稿日期:
2020-01-03
修回日期:
2020-04-29
发布日期:
2021-01-29
通讯作者:
陆前进
E-mail:qianlu5860@csu.edu.cn
基金资助:
Luo Shuaihantian, Long Hai, Zhang Guiying, Lu Qianjin
Received:
2020-01-03
Revised:
2020-04-29
Published:
2021-01-29
Contact:
Lu Qianjin
E-mail:qianlu5860@csu.edu.cn
Supported by:
摘要: 【摘要】 系统性红斑狼疮是一种主要累及中青年女性的自身免疫性疾病,临床表现复杂多样,可累及多器官系统。系统性红斑狼疮病因、诊断与治疗的研究一直是该领域的热点。2019年,国内外研究者在其发病机制、诊断和评估以及治疗方面取得了一系列新进展,本文就主要代表性成果进行综述。
罗帅寒天 龙海 张桂英 陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021,54(2):183-186. doi:10.35541/cjd.20200013
Luo Shuaihantian, Long Hai, Zhang Guiying, Lu Qianjin. Advances in systemic lupus erythematosus in 2019[J]. Chinese Journal of Dermatology, 2021, 54(2): 183-186.doi:10.35541/cjd.20200013
[1] | 罗帅寒天, 龙海, 陆前进. 2018年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2020,53(8):665⁃667. doi: 10.35541/cjd. 20190298. |
[2] | 陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展[J]. 中华皮肤科杂志, 2018,51(1):1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001. |
[3] | Smith KG, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications[J]. Nat Rev Immunol, 2010,10(5):328⁃343. doi: 10.1038/nri2762. |
[4] | Hu W, Zhang Y, Sun X, et al. FcγRIIB⁃I232T polymorphic change allosterically suppresses ligand binding[J]. Elife, 2019,8doi: 10.7554/eLife.46689. |
[5] | Alsaab HO, Sau S, Alzhrani R, et al. PD⁃1 and PD⁃L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017,8:561. doi: 10.3389/fphar.2017.00561. |
[6] | Han X, Vesely MD, Yang W, et al. PD⁃1H (VISTA)⁃mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus[J]. Sci Transl Med, 2019,11(522). doi: 10.1126/scitranslmed.aax1159. |
[7] | Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease[J]. Nature, 2016,535(7610):75⁃84. doi: 10.1038/nature18848. |
[8] | Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease⁃activity associated expansions and immunity to a gut commensal[J]. Ann Rheum Dis, 2019,78(7):947⁃956. doi: 10.1136/annrheumdis⁃2018⁃214856. |
[9] | Wu H, Huang X, Qiu H, et al. High salt promotes autoimmunity by TET2⁃induced DNA demethylation and driving the differentiation of Tfh cells[J]. Sci Rep, 2016,6:28065. doi: 10. 1038/srep28065. |
[10] | Zhang D, Jin W, Wu R, et al. High glucose intake exacerbates autoimmunity through reactive⁃oxygen⁃species⁃mediated TGF⁃β cytokine activation[J]. Immunity, 2019,51(4):671⁃681.e5. doi: 10.1016/j.immuni.2019.08.001. |
[11] | Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis[J]. Nat Rev Cancer, 2011,11(1):23⁃34. doi: 10.1038/nrc2986. |
[12] | Fu R, Xia Y, Li M, et al. Pim⁃1 as a therapeutic target in lupus nephritis[J]. Arthritis Rheumatol, 2019,71(8):1308⁃1318. doi: 10.1002/art.40863. |
[13] | Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019,78(9):1151⁃1159. doi: 10.1136/annrheumdis⁃2018⁃214819. |
[14] | Kaplan MJ, Radic M. Neutrophil extracellular traps: double⁃edged swords of innate immunity[J]. J Immunol, 2012,189(6):2689⁃2695. doi: 10.4049/jimmunol.1201719. |
[15] | Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus⁃like disease[J]. Nat Med, 2016,22(2):146⁃153. doi: 10.1038/nm.4027. |
[16] | Moore S, Juo HH, Nielsen CT, et al. Role of neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus[J]. J Rheumatol, 2019. doi: 10.3899/jrheum.19 0875. |
[17] | Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus[J]. Nat Commun, 2017,8:16021. doi: 10.1038/ncomms16021. |
[18] | Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus[J]. Ann Rheum Dis, 2020,79(3):363⁃369. doi: 10.1136/annrheumdis⁃2019⁃216227. |
[19] | Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index[J]. BMC Geriatr, 2008,8:24. doi: 10.1186/1471⁃2318⁃8⁃24. |
[20] | Legge A, Kirkland S, Rockwood K, et al. Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019,71(8):1297⁃1307. doi: 10.1002/art.40859. |
[21] | Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus[J]. Expert Opin Drug Saf, 2019,18(12):1133⁃1144. doi: 10.1080/14740338.2019.1685978. |
[22] | Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J]. Arthritis Rheumatol, 2019,71(7):1125⁃1134. doi: 10.1002/art.40861. |
[23] | Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis[J]. J Rheumatol, 2018,45(5):671⁃677. doi: 10.3899/jrheum.161554. |
[24] | Blankenship K. GlaxoSmithKline′s benlysta eyes lupus sales boost after kidney trial win[EB/OL]. [2019⁃12⁃18]. https://www.fiercepharma.com/pharma/glaxosmithkline⁃s⁃benlysta⁃scores⁃trial⁃win⁃patients⁃lupus⁃nephritis. |
[25] | Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First⁃Line Treatment of Follicular Lymphoma[J]. N Engl J Med, 2017,377(14):1331⁃1344. doi: 10.1056/NEJMoa1614598. |
[26] | Biogen Inc. Biogen announces positive phase 2 study results for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE)[EB/OL].[2019⁃12⁃3]. http://investors.biogen.com/news⁃releases/news⁃release⁃details/biogen⁃announces⁃positive⁃phase⁃2⁃study⁃results⁃cutaneous⁃lupus. |
[27] | Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP⁃1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4): e208⁃e219. doi: 10.1016/S2665⁃9913(19)30076⁃1. |
[28] | Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus[J]. N Engl J Med, 2020,382(3):211⁃221. doi: 10.1056/NEJMoa1912196. |
[29] | Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus[J]. J Clin Invest, 2019,129(3):1359⁃1371. doi: 10.1172/JCI124466. |
[30] | Roche Inc. FDA grants breakthrough therapy designation for Roche′s Gazyva (obinutuzumab) in lupus nephritis[EB/OL]. [2019⁃9⁃18]. https://www.roche.com/media/releases/med⁃cor⁃2019⁃09⁃18.htm. |
[31] | Mathian A, Pha M, Haroche J, et al. Withdrawal of low⁃dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial[J]. Ann Rheum Dis, 2020,79(3):339⁃346. doi: 10.1136/annrheumdis⁃2019⁃216303. |
[1] | 林羽洁, 刘凤洁, 高玉梅, 刘向君, 许卜方, 李映依, 赖盼, 陈卓婧, 孙婧茹, 涂平, 汪旸. 溶血磷脂酸受体6在蕈样肉芽肿向大细胞转变中的意义及其对皮肤T细胞淋巴瘤细胞增殖和凋亡的影响[J]. 中华皮肤科杂志, 2022, 55(2): 102-109. |
[2] | 王慧, 刘董, 田芳, 魏志平. 表皮生长因子受体shRNA联合西罗莫司对Colo-16细胞体外增殖、凋亡的研究[J]. 中华皮肤科杂志, 2022, 55(2): 135-141. |
[3] | 陈怡, 宋秀祖. 瞬时受体电位通道在黑素细胞中的作用及相关疾病研究[J]. 中华皮肤科杂志, 2022, 0(1): 20200958-e20200958. |
[4] | 张莹 李思琪 甘璐 孔英琪 李颜 陈浩 孙建方. 外周血流式细胞仪分析在淋巴瘤性红皮病诊断中的作用研究[J]. 中华皮肤科杂志, 2021, 54(9): 808-813. |
[5] | 中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770. |
[6] | 刘军麟 王薇 曹智睿 刘琨 万多艳 吴智明 罗杨 肖传柳 刘璐 殷梅. 基于靶基因捕获测序法对海南省汉族寻常型银屑病与维生素D受体基因关系的研究[J]. 中华皮肤科杂志, 2021, 54(7): 597-604. |
[7] | 虞英媛 李影 余增洋 郑建锋 张希琳 丁杨峰 史玉玲. 英夫利西单抗治疗重度斑块状银屑病的疗效和安全性及其对PD-1、PD-L1表达的影响[J]. 中华皮肤科杂志, 2021, 54(7): 590-596. |
[8] | 梁高澎 宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556. |
[9] | 魏子妤 侯霄枭 曹珂 李昕 叶枫 胡婷婷 莫小辉 陈广洁 Christos C. Zouboulis 鞠强. 白藜芦醇对苯并芘诱导的人皮脂腺细胞炎症因子及相关基因表达的影响[J]. 中华皮肤科杂志, 2021, 54(6): 469-474. |
[10] | 罗帅寒天 龙海 陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545. |
[11] | 渠莉田 苏惠春 程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466. |
[12] | 徐蓓蕾 姚煦. 过敏原特异性T细胞检测方法的研究进展[J]. 中华皮肤科杂志, 2021, 54(4): 364-367. |
[13] | 张悦昕 陈喜雪. 发生于特瑞普利单抗长期治疗后的大疱性类天疱疮二例[J]. 中华皮肤科杂志, 2021, 54(2): 131-135. |
[14] | 宋志强 王欢. 特应性皮炎的治疗进展:新药物、新手段、新模式[J]. 中华皮肤科杂志, 2021, 54(2): 161-164. |
[15] | 中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121. |
|